导师姓名：孙宏斌
性别：男
人气指数：500

所属院校：中国药科大学
所属院系：药物科学研究院
职称：教授
导师类型：博导
招生专业：药物化学
研究领域： （１）抗代谢性疾病药物研究；（２）抗肿瘤新药研究。
研究领域： （１）抗代谢性疾病药物研究；（２）抗肿瘤新药研究。 [收起]




通讯方式 :
办公电话：**
电子邮件：hongbinsun@cpu.edu.cn
通讯地址：南京市童家巷24号，中国药科大学 新药研究中心，邮编210009


个人简述 :
孙宏斌 (Hongbin Sun)，1966年12月出生。教育部“长江学者”特聘教授、博士生导师。现任“天然药物活性组分与药效”国家重点实验室副主任、江苏省代谢性疾病药物重点实验室主任、中国药科大学药物科学研究院新药研究中心主任，兼任国家基金委医学部“十三五”发展战略研究“药物学”专家组副组长、国家自然科学基金委医学部二审专家、中国药学会药物化学专业委员会委员、江苏省药学会药物化学专业委员会副主任委员、中国药科大学学位评定委员会和学术委员会委员、国家技术发明奖会议评审专家，担任Medicinal Chemistry、Recent Patents on Anti-Cancer Drug Discovery (2008-2015)、Drug Discoveries & Therapeutics（资深编委）、Acta Pharmaceutica Sinica B、中国药物化学杂志和中国药科大学学报等国内外期刊编委。 长期从事药物化学、有机合成化学和新药研究。基础研究课题主要包括两个方面：（1）脂代谢异常相关疾病的靶标确证及新药发现；（2）去泛素化酶（Deubiquitinase）的靶标确证及抗肿瘤新药研究。在新药开发方面，主持研制的国家1.1类抗血栓新药“维卡格雷”正在进行I期临床试验；主持研制的降血脂和抗脂肪肝新药OA在早期临床验证试验中显示了显著疗效。在国内外期刊发表论文184篇，其中SCI论文122篇；获授权专利 15项（其中美国和日本专利各1项）；参编著作5部；获1.1类新药临床批件2个。2005年入选教育部“新世纪优秀人才”；2006年获中国药学会“施维雅青年药物化学奖”；2007年获EFSD (欧洲糖尿病研究基金会) Grant Awards for Collaborative Diabetes Research between China and Europe；2012年入选教育部“长江学者奖励计划”；2013年入选江苏省“333高层次人才培养工程”第二层次培养对象；2014年作为团队负责人组建了“江苏省代谢性疾病药物重点实验室”；2016年当选江苏省有突出贡献的中青年专家（公示完毕）。自2004年以来，已培养毕业硕士生25人，毕业博士生18人，其中1人获2009年度中国药学会-施维雅青年药物化学奖，并获得全国优秀博士论文提名论文奖。目前承担博士生课程《药物立体化学》、硕士生课程《药物化学选论》和本科生课程《药物设计》的教学工作。

科研工作 :
代表性论文：1.Omid Tavana, Dawei Li, Chao Dai, Gonzalo Lopez, Debarshi Banerjee, Ning Kon, Chao Chen, Andrea Califano, Darrell J Yamashiro, Hongbin Sun, Wei Gu *. Destabilizing N-Myc by HAUSP Inhibition Acts as a Potential Therapy for Neuroblastomas. Nature Medicine 2016, accepted. 2.Jin-Zheng Wang, Jin Zhou, Chang Xu, Hongbin Sun*, László Kürti* and Qing-Long Xu.* Symmetry in Cascade Chirality-Transfer Processes: A Catalytic Atroposelective Direct Arylation Approach to BINOL Derivatives. J. Am. Chem. Soc. 2016, 138, 5202-5205.3.Zhuang Song, Yizhou Wu, Tao Xin, Xiaoan Wen, Hongbin Sun,* and Qing-Long Xu.* Rh(II)-Catalyzed Formal N-S Bond Insertion Reaction of Aryldiazoacetates into N-Phenyl-Sulfenyl Phthalimide. Chemical Communications 2016, 52, 6079-6082.4.Ming Yang, Xiaowen Yang, Hongbin Sun, Ang Li*. Total Synthesis of Ileabethoxazole, Pseudopteroxazole, and seco-Pseudopteroxazole. Angewandte Chemie International Edition 2016, 55, 2851-2855.5.Xiantao Lei, Hong-Yan Xie, Chang Xu, Xiaoyu Liu, Xiaoan Wen, Hongbin Sun*, Qing-Long Xu*. Dearomatization of Indoles Derivatives via Pd-Catalyzed C-H Bond Functionalization of Pyrroles: Convenient Construction of Spiroindolenines. Advanced Synthesis & Catalysis 2016, 358, 1892-1896 (Very Important Publication).6.Chao Lin, Le Zhen, Yong Cheng, Hong-Jin Du, Hui Zhao, Xiaoan Wen, Lingyi Kong, Qing-Long Xu*, Hongbin Sun*. Visible-light Induced Isoindoles Formation to Trigger Intermocular Diels-Alder Reactions In the Presence of Air. Organic letters 2015, 17, 2684-2687. 7.Xiaowei Sun, Xiaoan Wen, Yan-yan Chen, Chen Shi, Chengzhe Gao, Yong Wu, Li-jun Wang, Xiu-hong Yang*, Hongbin Sun*. Discovery of highly potent renin inhibitors potentially interacting with the S3′subsite of renin. European Journal of Medicinal Chemistry 2015, 103, 269-288.8.Xueli Zhang, Yanli Tian, Can Zhang, Xiaoyu Tian, Alana W. Ross, Robert D. Moir, Hongbin Sun, Rudolph E. Tanzi, Anna Moore, Chongzhao Ran*. Near-infrared fluorescence molecular imaging of amyloid beta species and monitoring therapy in animal models of Alzheimer’s disease. PNAS 2015, 112, 9734-9739.9.Peng-Fei Wang, Chun-Huan Jiang, Xiaoan Wen, Qing-Long Xu,* Hongbin Sun.*C-H Bond Functionalization via [1,5]-Hydride Shift/Cyclization Sequence: Approach to Spiroindolenines. Journal of Organic Chemistry 2015, 80, 1155-1162. 10.Yong-Zhi Chang, Ming-Lei Li, Wen-Feng Zhao, Xiaoan Wen, Hongbin Sun,* Qing-Long Xu*. Construction of Oxadiazepines via Lewis Acid-Catalyzed Tandem 1,5-Hydride Shift/Cyclization. Journal of Organic Chemistry 2015, 80, 9620-9627.11.Fan Zhang, Hengzhi Sun, Zhuang Song, Shuxi Zhou, Xiaoan Wen, Qing-Long Xu,* Hongbin Sun.* Stereoselective Synthesis of Arylglycine Derivatives via a Palladium-Catalyzed alpha-Arylation of Chiral Nickel (II) Glycinate. Journal of Organic Chemistry 2015, 80, 4459?4464.12.Zengwei Lai, Chunhong Li, Jun Liu, Lingyi Kong, Xiaoan Wen,* Hongbin Sun.* Discovery of Highly Potent DPP-4 Inhibitors by Hybrid Compound Design Based on Linagliptin and Alogliptin. European Journal of Medicinal Chemistry 2014, 83, 547-560. 13.Xueli Zhang, Yanli Tian, Zeng Li, Xiaoyu Tian, Hongbin Sun, Hong Liu, Anna Moore, Chongzhao Ran*. Design and synthesis of curcumin analogues for in vivo fluorescence imaging and inhibiting copper-induced cross-linking of amyloid Beta species in Alzheimer's disease. J. Am. Chem. Soc. 2013, 135, 16397-409.14.Jiaqi Shan, Boyu Zhang, Yaoqiu Zhu, Bo Jiao, Weiyi Zheng, Xiaowei Qi, Yanchun Gong,Fang Yuan, Fusheng Lv, Hongbin Sun.* Overcoming Clopidogrel Resistance: Discovery of Vicagrel as a Highly Potent and Orally Bioavailable Antiplatelet agent. Journal of Medicinal Chemistry 2012, 55, 3342–3352.（获Nature旗下刊物SciBX的亮点报道）15.Huaming Sheng, Hongbin Sun.* Synthesis, Biology and Clinical Significance of Pentacyclic Triterpenes: a Multi-target Approach to Prevention and Treatment of Metabolic and Vascular Diseases.Natural Product Reports 2011, 28, 543-593.16.Zhangyu Yao, Xueying Wei, Xiaoming Wu, Jonathan L. Katz, Theresa Kopajtic, Nigel H. Greig, Hongbin Sun.* Preparation and Evaluation of Tetrabenazine Enantiomers and All Eight Stereoisomers of Dihydrotetrabenazine as VMAT2 Inhibitors. European Journal of Medicinal Chemistry 2011, 46, 1841-1848. 17.Zhongjie Liang, Liying Zhang, Lianchun Li, Jun Liu, Honglin Li, Luyong Zhang，Keguang Cheng, Xiaoan Wen, Pu Zhang, Jia Hao, Yanchun Gong, Xia Zhang, Jun Chen, Hong Liu, Cheng Luo, Hualiang Jiang, Hongbin Sun.* Pentacyclic Triterpenes Derivatives as Potent Inhibitors against Glycogen Phosphorylase: the Receptor-Based 3D-QSAR Guided Inhibitor Optimization. European Journal of Medicinal Chemistry 2011, 46, 2011-2021.

教育背景 :
1989年毕业于吉林大学化学系；1995年获中国药科大学博士学位；1995-2001年先后在中科院上海有机化学研究所、德国亚琛工业大学有机化学研究所和美国佛罗里达大学化学系从事博士后研究。